These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 35682999)

  • 21. Longitudinal Multi-Parametric Liquid Biopsy Approach Identifies Unique Features of Circulating Tumor Cell, Extracellular Vesicle, and Cell-Free DNA Characterization for Disease Monitoring in Metastatic Breast Cancer Patients.
    Keup C; Suryaprakash V; Storbeck M; Hoffmann O; Kimmig R; Kasimir-Bauer S
    Cells; 2021 Jan; 10(2):. PubMed ID: 33494385
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Sensitive and robust liquid biopsy-based detection of PIK3CA mutations in hormone-receptor-positive metastatic breast cancer patients.
    Suppan C; Graf R; Jahn S; Zhou Q; Klocker EV; Bartsch R; Terbuch A; Kashofer K; Regitnig P; Lindenmann J; Posch F; Gerritsmann H; Jost PJ; Heitzer E; Dandachi N; Balic M
    Br J Cancer; 2022 Feb; 126(3):456-463. PubMed ID: 34754095
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Analysing the mutational status of PIK3CA in circulating tumor cells from metastatic breast cancer patients.
    Schneck H; Blassl C; Meier-Stiegen F; Neves RP; Janni W; Fehm T; Neubauer H
    Mol Oncol; 2013 Oct; 7(5):976-86. PubMed ID: 23895914
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Shallow WGS of individual CTCs identifies actionable targets for informing treatment decisions in metastatic breast cancer.
    Fernandez-Garcia D; Nteliopoulos G; Hastings RK; Rushton A; Page K; Allsopp RC; Ambasager B; Gleason K; Guttery DS; Ali S; Charles Coombes R; Shaw JA
    Br J Cancer; 2022 Nov; 127(10):1858-1864. PubMed ID: 36088510
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Monitoring of cancer patients via next-generation sequencing of patient-derived circulating tumor cells and tumor DNA.
    Onidani K; Shoji H; Kakizaki T; Yoshimoto S; Okaya S; Miura N; Sekikawa S; Furuta K; Lim CT; Shibahara T; Boku N; Kato K; Honda K
    Cancer Sci; 2019 Aug; 110(8):2590-2599. PubMed ID: 31169336
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Genomic Landscape of Circulating-Tumor DNA in a Diverse Cohort of Metastatic Breast Cancer Patients.
    Cheng S; Nguyen ET; Pagano I; Fukui JA
    Oncol Res Treat; 2023; 46(1-2):26-32. PubMed ID: 36481616
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Circulating PIK3CA mutation detection at diagnosis in non-metastatic inflammatory breast cancer patients.
    Allouchery V; Perdrix A; Calbrix C; Berghian A; Lequesne J; Fontanilles M; Leheurteur M; Etancelin P; Sarafan-Vasseur N; Di Fiore F; Clatot F
    Sci Rep; 2021 Dec; 11(1):24041. PubMed ID: 34911971
    [TBL] [Abstract][Full Text] [Related]  

  • 28.
    Mastoraki S; Strati A; Tzanikou E; Chimonidou M; Politaki E; Voutsina A; Psyrri A; Georgoulias V; Lianidou E
    Clin Cancer Res; 2018 Mar; 24(6):1500-1510. PubMed ID: 29284708
    [No Abstract]   [Full Text] [Related]  

  • 29. Association of a novel circulating tumor DNA next-generating sequencing platform with circulating tumor cells (CTCs) and CTC clusters in metastatic breast cancer.
    Davis AA; Zhang Q; Gerratana L; Shah AN; Zhan Y; Qiang W; Finkelman BS; Flaum L; Behdad A; Gradishar WJ; Platanias LC; Cristofanilli M
    Breast Cancer Res; 2019 Dec; 21(1):137. PubMed ID: 31801599
    [TBL] [Abstract][Full Text] [Related]  

  • 30. PIK3CA mutations in plasma circulating tumor DNA predict survival and treatment outcomes in patients with advanced cancers.
    Dumbrava EE; Call SG; Huang HJ; Stuckett AL; Madwani K; Adat A; Hong DS; Piha-Paul SA; Subbiah V; Karp DD; Fu S; Naing A; Tsimberidou AM; Moulder SL; Koenig KH; Barcenas CH; Kee BK; Fogelman DR; Kopetz ES; Meric-Bernstam F; Janku F
    ESMO Open; 2021 Oct; 6(5):100230. PubMed ID: 34479035
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Comprehensive liquid biopsy analysis as a tool for the early detection of minimal residual disease in breast cancer.
    Stergiopoulou D; Markou A; Strati A; Zavridou M; Tzanikou E; Mastoraki S; Kallergi G; Georgoulias V; Lianidou E
    Sci Rep; 2023 Jan; 13(1):1258. PubMed ID: 36690653
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Genomic high-resolution profiling of single CKpos/CD45neg flow-sorting purified circulating tumor cells from patients with metastatic breast cancer.
    Neves RP; Raba K; Schmidt O; Honisch E; Meier-Stiegen F; Behrens B; Möhlendick B; Fehm T; Neubauer H; Klein CA; Polzer B; Sproll C; Fischer JC; Niederacher D; Stoecklein NH
    Clin Chem; 2014 Oct; 60(10):1290-7. PubMed ID: 25267515
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Evaluation of Circulating Tumor DNA in Patients with Ovarian Cancer Harboring Somatic PIK3CA or KRAS Mutations.
    Ogasawara A; Hihara T; Shintani D; Yabuno A; Ikeda Y; Tai K; Fujiwara K; Watanabe K; Hasegawa K
    Cancer Res Treat; 2020 Oct; 52(4):1219-1228. PubMed ID: 32599986
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Circulating Tumor Cell and Circulating Tumor DNA Assays Reveal Complementary Information for Patients with Metastatic Urothelial Cancer.
    Chalfin HJ; Glavaris SA; Gorin MA; Kates MR; Fong MH; Dong L; Matoso A; Bivalacqua TJ; Johnson MH; Pienta KJ; Hahn NM; McConkey DJ
    Eur Urol Oncol; 2021 Apr; 4(2):310-314. PubMed ID: 31563523
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Development and verification of a three-dimensional (3D) breast cancer tumor model composed of circulating tumor cell (CTC) subsets.
    Anil-Inevi M; Sağlam-Metiner P; Kabak EC; Gulce-Iz S
    Mol Biol Rep; 2020 Jan; 47(1):97-109. PubMed ID: 31583566
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Genetic landscape of breast cancer and mutation tracking with circulating tumor DNA in Chinese women.
    Wang Y; Lin L; Li L; Wen J; Chi Y; Hao R; Dai X; Chen Y; Huang D; Zhou Y; You J; Ye Z; Chen H; Jin L; Chen D; Yang F; Xia E; Ma X; Guo F; Tong Y; Zheng M; Wang O
    Aging (Albany NY); 2021 Apr; 13(8):11860-11876. PubMed ID: 33893247
    [TBL] [Abstract][Full Text] [Related]  

  • 37. ctDNA dynamics: a novel indicator to track resistance in metastatic breast cancer treated with anti-HER2 therapy.
    Ma F; Zhu W; Guan Y; Yang L; Xia X; Chen S; Li Q; Guan X; Yi Z; Qian H; Yi X; Xu B
    Oncotarget; 2016 Oct; 7(40):66020-66031. PubMed ID: 27602761
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Mutational analysis of single circulating tumor cells by next generation sequencing in metastatic breast cancer.
    De Luca F; Rotunno G; Salvianti F; Galardi F; Pestrin M; Gabellini S; Simi L; Mancini I; Vannucchi AM; Pazzagli M; Di Leo A; Pinzani P
    Oncotarget; 2016 May; 7(18):26107-19. PubMed ID: 27034166
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Drainage of Tumor-Derived DNA into Sentinel Lymph Nodes in Breast Cancer Patients.
    Miyamura Y; Kagara N; Miyake T; Tanei T; Naoi Y; Shimoda M; Shimazu K; Kim SJ; Noguchi S
    Pathol Oncol Res; 2019 Oct; 25(4):1635-1643. PubMed ID: 30805870
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Molecular characterization of breast cancer CTCs associated with brain metastasis.
    Boral D; Vishnoi M; Liu HN; Yin W; Sprouse ML; Scamardo A; Hong DS; Tan TZ; Thiery JP; Chang JC; Marchetti D
    Nat Commun; 2017 Aug; 8(1):196. PubMed ID: 28775303
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.